Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F11%3A00003553" target="_blank" >RIV/00216208:11120/11:00003553 - isvavai.cz</a>
Alternative codes found
RIV/61389005:_____/11:00365501 RIV/00216208:11160/11:10100351
Result on the web
<a href="http://dx.doi.org/10.1089/cbr.2010.0916" target="_blank" >http://dx.doi.org/10.1089/cbr.2010.0916</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1089/cbr.2010.0916" target="_blank" >10.1089/cbr.2010.0916</a>
Alternative languages
Result language
angličtina
Original language name
Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors
Original language description
The humanized monoclonal antibody Nimotuzumab (h-R3) has demonstrated an exceptional and better clinical profile than other monoclonal antibodies for immunotherapy of epidermal growth factor receptor-overexpressing tumors. This work deals with the preparation and radiolabeling optimization of (177)Lu-Nimotuzumab and their preclinical evaluation. Nimotuzumab was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), testing different molar ratios. The immunoconjugates were characterized. The radiolabeling with (177)Lu was optimized. Radioimmunoconjugates stability was tested in 2-[bis[2-[bis(carboxymethyl)amino]ethyl]amino]acetic acid (DTPA) excess and human serum. In vitro studies were performed intumor model cell lines. Receptor-specific binding was tested by competitive inhibition. (177)Lu-Nimotuzumab in vivo studies were conducted in healthy and xenograft animals. (177)Lu-Nimotuzumab was obtained with high purity and specific a
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/OE08018" target="_blank" >OE08018: Radionuclide precursors and radiopharmaceuticals for targeted radionuclide imaging and therapy</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cancer Biotherapy and Radiopharmaceuticals
ISSN
1084-9785
e-ISSN
—
Volume of the periodical
26
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
287-297
UT code for WoS article
000292447100005
EID of the result in the Scopus database
—